Zimmer Biomet Reports Q3 2026 Growth Driven by Hips and S.E.T. Segments
Zimmer Biomet (ZBH) reported third-quarter net sales of $2.063 billion, marking a 3.1% reported increase driven primarily by strong performance in the Hip and S.E.T. segments. While the Knee business faced a 2.6% constant currency decline due to distributor consolidation in China and sales force transitions, growth in technology and data solutions reached 13%, bolstered by a 20% surge in robotics and AI-driven products. Despite flat year-over-year adjusted diluted EPS of $1.90—impacted by investments in the U.S. commercial organization and manufacturing costs—the company raised its full-year organic constant currency revenue guidance to 3.0%-3.5%. Free cash flow saw a significant boost, increasing 34% year-over-year to $372.4 million, reflecting strong operational execution despite headwinds in the Chinese market.
Tickers: $ZBH
Topics: adjusted eps hip segment growth knee segment decline net sales segment performance